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Copy number variation (CNV) is known to cause all von Willebrand disease (VWD) types,
although the associated pathogenicmechanisms involved have not been extensively studied.
Notably, in-frame CNV provides a unique opportunity to investigate how specific von
Willebrand factor (VWF) domains influence the processing and packaging of the protein.
Using multiplex ligation-dependent probe amplification, this study determined the extent to
which CNV contributed to VWD in the Molecular and Clinical Markers for the Diagnosis and
Management of Type 1 von Willebrand Disease cohort, highlighting in-frame deletions of
exons 3, 4-5, 32-34, and 33-34. Heterozygous in vitro recombinant VWF expression
demonstrated that, although deletion of exons 3, 32-34, and 33-34 all resulted in significant
reductions in total VWF (P, .0001, P, .001, and P, .01, respectively), only deletion of exons
3 and 32-34 had a significant impact on VWF secretion (P , .0001). High-resolution
microscopy of heterozygous and homozygous deletions confirmed these observations,
indicating that deletion of exons 3 and 32-34 severely impaired pseudo-Weibel-Palade body
(WPB) formation, whereas deletion of exons 33-34 did not, with this variant still exhibiting
pseudo-WPB formation similar to wild-type VWF. In-frame deletions in VWD, therefore,
contribute to pathogenesis via moderate or severe defects in VWF biosynthesis
and secretion.
Introduction
von Willebrand disease (VWD), a common autosomal inherited bleeding disorder, results from mild or
moderate (type 1; VWD1) or severe (type 3; VWD3) quantitative, or functional (type 2; VWD2) deficiency of
plasma von Willebrand factor (VWF).1 Accurate identification and characterization of disease-causing
variants in VWD are essential to fully understand the molecular mechanisms contributing to pathogenesis.2
Both VWD1 and VWD2 are caused predominantly by heterozygous variants within the VWF gene.3
Historically, the variant screening approaches used in studies of VWD1 and VWD2 were unable to
identify heterozygous copy number variation (CNV; large deletions and/or duplications) because
polymerase chain reaction (PCR)-based methodologies also amplify the wild-type (WT) allele, masking
the presence of heterozygous CNV. Most identified CNV were therefore homozygous and reported in
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VWD3, resulting in a protein coding frameshift and lack of VWF
expression.2,3 Several studies have now used multiplex ligation-
dependent probe amplification (MLPA) screening of VWF to
identify large homozygous and heterozygous CNV in patients
with VWD1-3.4-14 However, to date, the pathogenic mechanisms
have only been investigated for 4 of 33 (12%) of identified CNV;
deletions of exons 4-5,15,16 26-34,17 and 32-34,18 and an exon 9-10
duplication.12
Using MLPA, this study aimed to determine the prevalence of CNV
in a cohort of patients historically diagnosed with VWD1 recruited
by the European study Molecular and Clinical Markers for the Di-
agnosis and Management of Type 1 VWD (MCMDM-1VWD). Sub-
sequently we characterized identified CNV using in vitro expression
and high-resolution microscopy, which highlighted that CNV have
varying impacts on VWF biosynthesis, storage, and secretion.
Methods
Local ethics review committees at each center approved the study
protocol. In accordance with the Declaration of Helsinki, informed
consent was obtained from all individuals at recruitment by the
individual signing a consent form in their own language.
Study population and phenotypic analysis
Index cases (IC), along with affected and unaffected family
members, were recruited as part of the MCMDM-1VWD study as
previously described.19 Available phenotypic data for VWF antigen
(VWF:Ag), ristocetin cofactor activity (VWF:RCo), collagen binding
(VWF:CB), propeptide (VWFpp), factor VIII procoagulant activity
(FVIII:C), binding of VWF to FVIII (VWF:FVIIIB), and bleeding score
(BS) were measured as previously described.20-24 Multimer anal-
ysis of plasma samples was performed using sodium dodecyl
sulfate (SDS)–agarose gel electrophoresis as described.25
Generation of VWF CNV expression plasmids
Plasmids expressing VWF CNV (exon 3 deletion, c.56_220del;
exon 32-34 deletion, c.5456_5842del; exon 33-34 deletion,
c.5621_5842del) were generated in a pCI-neo mammalian ex-
pression plasmid (Promega UK Ltd., Southampton, United Kingdom
[UK]) containing full-length WT VWF cDNA (pCI-neo-VWF) using a
QuikChange Lightning Site-Directed Mutagenesis Kit (Agilent Tech-
nologies LDA UK Ltd., Stockport, UK). Successful mutagenesis was
confirmed via DNA sequence analysis.
In vitro recombinant VWF (rVWF) expression
HEK293 cells were maintained in Dulbecco’s modified Eagle me-
dium containing GlutaMAX supplemented with 10% volume-to-
volume ratio (vol/vol) fetal bovine serum (Thermo Fisher Scientific,
Paisley, UK). Transient cell transfections with 700 ng/mL WT pCI-
neo-VWF or mutant VWF CNV expression plasmid (or 350 ng/mL
of both plasmids for 50:50 cotransfections) were performed using
either Lipofectamine LTX reagent (Thermo Fisher Scientific) or
Xfect (Takara Bio Europe S.A.S, Saint-Germain-en-Laye, France)
according to the manufacturer’s recommendations. Cells were
maintained at 37°C/5%CO2 for 24 hours before culture media was
replaced. Following a further 48-hour incubation, culture media was
collected, and the cells were lysed in 300 mL of 13 passive lysis
buffer (Promega) containing a protease inhibitor cocktail (Sigma-
Aldrich Co. Ltd., Poole, UK).
VWF:Ag levels from cellular supernatants and intracellular lysates
were evaluated by enzyme-linked immunosorbent assay (ELISA)
using the matched pair VWF:Ag capture and detection antibody kit
(Enzyme Research Laboratories Ltd., Swansea, UK). Total VWF:Ag
(lysate plus supernatant) was calculated for WT and each mutant
and was expressed as a percentage of WT total (WT 5 100%).
The secreted/retained VWF:Ag ratios (VWF in supernatant/VWF in
lysate) were normalized to WT (WT ratio given as 1). VWF multimer
analysis on 1.6% medium resolution SDS-agarose gels was
performed on cellular supernatants as previously described.25
To determine the ability of the mutants to release VWF after
extrinsic stimulation, HEK293 cells were transfected with plasmids
as described above, and 72 hours post-transfection the cells were
incubated with 160 nM phorbol 12‐myristate 13‐acetate (PMA;
Sigma‐Aldrich) or vehicle (dimethyl sulphoxide [DMSO]). The amount
of VWF released in 1 hour was determined by the percentage of
VWF secreted in medium over the total VWF levels.
Immunocytochemistry and fluorescence microscopy
Microscopy was performed on HEK293 cells 72 hours posttrans-
fection. Cells were fixed using BD Cytofix/Cytoperm (BD Bio-
sciences, Wokingham, UK) at room temperature for 20 minutes,
washed 3 times with PBS and 1 time3 with 50 mM NH4Cl, and
permeabilized with 0.2% vol/vol Triton X-100. Cells were then
blocked with 5% vol/vol goat serum (Sigma-Aldrich), washed
3 times with PBS, and incubated at room temperature for 1 hour
with primary antibodies at the following concentrations: polyclonal
rabbit antihuman VWF at 1:1000 (Dako [UK] Ltd., Ely, UK), mouse
antihuman calnexin at 1:500 (Abcam, Cambridge, UK), and sheep
antihuman TGN46 at 1:250 (Bio-Rad AbD Serotec Ltd., Kidlington,
UK). Following incubation, cells were washed 3 times with 5% vol/vol
goat serum and twice with PBS before incubation with 1:500
secondary antibodies (goat antirabbit IgG Alexa Fluor 488, goat
antimouse IgG Alexa Fluor 555/568, and donkey antisheep IgG Alexa
Fluor 647; Thermo Fisher Scientific) at room temperature for 1 hour.
Finally, cells were washed 3 times with 5% vol/vol goat serum and
3 times with PBS before mounting with ProLong Gold Antifade
Mountant (Thermo Fisher Scientific).
Widefield images were captured on a Nikon TiE inverted micro-
scope with a 1003 oil objective and Andor Zyla scientific comple-
mentary metal oxide semiconductor (sCMOS) camera. Image files
were processed in Fiji26 to make minor adjustments to contrast and
brightness, and are presented as maximum intensity projections.
Structured illumination microscopy (SIM) was carried out using
a Deltavision V4 OMX 3D-SIM system fitted with a Blaze module
(Applied Precision, GE Healthcare, Issaquah, WA) and a 603 1.42
oil planapochromat objective/lens. The system used a standard
blue-green-red filter set and used front illuminated sCMOS cameras
(2560 3 2160 pixels; pixel size, 6.45 mm; readout speed, 95-286
Mhz; operated at 5123 512 pixels, 15 bit for 3D-SIM imaging). SIM
samples were illuminated using patterned laser illumination at 488
nm. For each z slice, samples were imaged in 5 phase shifts and
3 angles, and z steps were 0.125 nm. Reconstruction and alignment
of the subsequent Moiré fringe raw image data were performed in
SoftWoRx v6.5.2 (GE Healthcare) using optical transfer functions
optimized for the specific wavelength and oil used. All raw images
were processed in Fiji.26
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Statistical and in silico analysis
Statistical analysis was performed in GraphPad Prism v.7.03 (Graph-
Pad Software Inc., La Jolla, CA). In silico analysis to investigate signal
peptide (SP) cleavage was performed using SignalP v4.1.27
Results
Identification of CNV in VWD patients
Of the 150 MCMDM-1VWD IC originally recruited,19 104 were
screened for the presence of CNV using MLPA (supplemental
Methods), specifically those with no previously identified causative
variant or with a variant identified that failed to fully explain the observed
clinical phenotype. Analysis identified 6 heterozygous deletions
(supplemental Figure 1), specifically of exon 3 (ex3del), exons 4-5 (in
3 IC; ex4-5del), exons 32-34 (ex32-34del), and exons 33-34 (ex33-
34del). Table 1 details the phenotypic characteristics of the 6 IC.
The ex4-5del and ex32-34del IC had no previously identified variant.
Heterozygous inheritance of c.8164C.G (p.Pro2722Ala) was
previously reported in the ex3del IC.19 This variant was originally
considered to be pathogenic because it segregated with disease
phenotype19 and has a population frequency ,0.0001%.28 How-
ever in vitro, p.Pro2722Ala had no effect on VWF expression
compared with WT (supplemental Methods; supplemental Fig-
ure 2). The ex33-34del IC was previously found to be heterozygous
for the known VWF variant c.2561G.A (p.Arg854Gln),19 but this
variant did not segregate with disease phenotype in the family.
Exact deletion breakpoints (c.221-977_53217059del) had pre-
viously been reported for a characterized ex4-5del shown to occur
in VWD1 and VWD3 patients.15,16 The PCR-based assay designed
specifically for this deletion15 confirmed that the same ex4-5del
occurred in the 3 MCMDM-1VWD IC and segregated with disease
phenotype in the respective families (Table 1; supplemental Methods;
supplemental Figure 3). The breakpoints for the other identified
deletions were mapped within VWF (supplemental Methods), with all
3 deletions shown to be in-frame (Table 1). PCR-based assays for
these 3 deletions confirmed that they all segregated with disease
phenotype, and additional in silico analysis highlighted the likely
mechanisms by which the deletions arose (supplemental Methods;
supplemental Figures 3 and 4).
Characterization of heterozygous VWF CNV
The ex4-5del has been characterized extensively in previous in vitro and
in vivo studies.15,16 Therefore, in vitro expression (and subsequent high-
resolution microscopy) analyses focused on ex3del, ex32-34del, and
ex33-34del characterization. ELISA analysis and quantification of
supernatants and lysates was used to calculate the total VWF:Ag
present. Heterozygous expression of the 3 deletions (mimicking the
inheritance pattern observed in the IC) demonstrated that, in compar-
ison with WT, expression of rVWF for ex3del (rVWF3del) and ex32-
34del (rVWF32-34del) resulted in a significant decrease in total VWF:
Ag (;60% reduction [P , .0001] and ;50% reduction [P , .001],
respectively; Figure 1A). In comparison, reduction in total VWF
observed for the expression of ex33-34del (rVWF33-34del) wasmilder
yet still significant (;40% reduction [P, .01]; Figure 1A). Despite the
reduction in total VWF, the deletions did not result in significantly
altered VWF lysate levels compared with WT (P . .05; Figure 1B).
Quantification of secreted VWF demonstrated that rVWF3del and
rVWF32-34del expression also had a profound effect on secretion,
resulting in ratios of 0.41 and 0.36, respectively; significant
reductions compared with WT (P , .0001; Figure 1C). Additional
WT/mutant titration experiments indicated that both affected VWF
secretion in a dominant-negative manner (supplemental Figure 5).
In contrast, analysis of rVWF33-34del expression revealed that
reduction in total VWF was a more significant contributor to reduced



















group BS* Multimers† Variant Exons deleted
P1F5III1 28 28 1.00 40 1.43 29 70 1.12 O/A 4 Normal c.221-977_53217059del
(p.Asp75_Gly178del)
4-5




P6F10II1 28 29 0.97 58 2.00 44 65 1.06 O/A 14 Normal c.221-977_53217059del
(p.Asp75_Gly178del)
4-5




P9F11II1|| 20 31 0.65 47 1.52 31 5 0.95 O/O 10 Normal c.56-335_22011585del
(p.Thr20_Gly74del)
3
P12F9III1 27 21 1.29 41 1.95 30 58 1.12 O/O 8 Normal c.221-977_53217059del
(p.Asp75_Gly178del)
4-5
Normal range{ 75-117 76-121 0.85-1.17 104-136 1.00-1.50 103-150 88-133 0.68-1.44 — — — — —
—, not applicable; pp/Ag, VWFpp/VWF:Ag ratio; RCo/Ag, VWF:RCo/VWF:Ag ratio.
*A score $4 is indicative of excessive bleeding.23
†Based on detailed analysis (P6F1II1 reclassified as VWD2A).25
‡IC were also heterozygous for c.2561G.A (p.Arg854Gln) in trans.
§A detailed description of deletion is provided in supplemental Figure 4.
||IC were also heterozygous for c.8164C.G (p.Pro2722Ala) in cis.
{Based on the analysis of healthy control individuals.19,24
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VWF levels than a defect in secretion with a ratio of 0.8 (Figure 1C).
Given that the expression data indicated an influence of both VWF
biosynthesis (total VWF) and secretion, the combined influence of
both was considered a more accurate representation of the patient
phenotype. Calculation of this effective secretion (secretion ratio 3
percentage of WT) highlighted significant reductions of ;80% for
both rVWF3del and rVWF32-34del, and a reduction of ;50%
for rVWF33-34del compared with WT (P , .0001; Figure 1D).
Secreted multimers displayed a full VWF profile similar to WT for all
deletions (supplemental Figure 6), although for rVWF32-34del and
rVWF33-34del there was an apparent reduction in intensity of the
high molecular weight (HMW) VWF similar to that observed in the
respective IC (supplemental Figure 6B,C).
Expression of WT rVWF resulted in the formation of pseudo-
Weibel-Palade bodies (WPB) that were clearly visible as elongated
VWF-positive structures under widefield fluorescence microscopy,
often in close proximity to or emerging from the trans-Golgi network
(TGN; Figure 2A-D). Heterozygous rVWF3del expression formed
some pseudo-WPB, but these were fewer in number compared
with WT, with additional diffuse VWF staining localized to the endo-
plasmic reticulum (ER; Figure 2E-H). Unlike rVWF3del, rVWF32-
34del expression highlighted no diffuse ER localization; however, the
pseudo-WPB demonstrated increased clustering around the Golgi/
TGN (Figure 2I-L). In contrast to the other deletions, rVWF33-34del
expressed pseudo-WPB similar to WT in both appearance and
localization (Figure 2M-P).
Characterization of homozygous VWF CNV
Given that the deletions were all in-frame, homozygous expression
allowed for their impact on VWF biosynthesis, storage, and secre-








































































































































































































































































Figure 1. In vitro expression of recombinant in-frame deletions. (A) Quantification of total VWF:Ag as a percentage of WT. (B) Quantification of total VWF:Ag as
a percentage of WT (expressed as a proportion of lysate and supernatant). (C) VWF secretion ratios normalized to WT (ratio, 1.0). (D) Effective secretion of VWF normalized
to WT (100%). Data were analyzed using 1-way ANOVA and Dunnett’s posttest multiple comparison with WT (**P , .01; ***P , .001; ****P , .0001). Mean values for n 5 3
triplicate measurements are shown (bars indicate standard error of the mean). Het, heterozygous; Hom, homozygous; ns, not significant.
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regarding potential pathogenic mechanisms. Both rVWF3del and
rVWF32-34del expression demonstrated significant effects on total
VWF:Ag (.90% and ;88% reduction, respectively [P , .0001];
Figure 1A) and secreted VWF (ratios 0.016 and 0.1, respectively
[P , .0001]; Figure 1C), resulting in a lack of effective secretion
(P , .0001; Figure 1D; supplemental Figure 6A-B). Widefield
microscopy highlighted that, compared with WT (Figure 3A-D),
rVWF3del was unable to form pseudo-WPB and instead produced
a diffuse staining pattern highly suggestive of ER retention of VWF
(Figure 3E-H). Although rVWF32-34del expression also showed
ER-localized VWF staining with no identifiable pseudo-WPB,
VWF-positive structures were apparent (Figure 3I-L).
Under SIM analysis, WT pseudo-WPB were ;1 to 2 mm in length
with a distinctive hollow appearance and bright VWF staining along
the outer membrane (Figure 4A-B). Significant variation in shape
VWF ER Golgi Merge





E F G H
I J K L
M N O P
Figure 2. Widefield fluorescence microscopy of recombinant heterozygous in-frame deletions. HEK293 cells were transfected with WT rVWF only (A-D) and WT
rVWF with either rVWF3del (E-H), rVWF32-34del (I-L), or rVWF33-34del (M-P) in a 1:1 ratio. Cells were fixed and stained for VWF (green), ER (red), and Golgi (magenta).
Scale bars, 5 mm.
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and size of these structures was observable, with some appearing
as short round structures and others formed in the classic
elongated cigar shape. For rVWF3del expression, SIM analysis
revealed a network-like structure of VWF, presumably reflecting its
location, interspersed within the ER (Figure 4C-D). In contrast, SIM
analysis revealed that rVWF32-34del expression formed VWF-
positive puncta, more accurately described as VWF aggregates
(Figure 4E-F). These were clearly distinct from pseudo-WPB in that
they were disordered, random accumulations of VWF, without the
characteristic hollow appearance observed in the WT pseudo-
WPB (Figure 4B). Instead, the VWF-positive signal exhibited a
bright uniform intensity across the entire structure (Figure 4F), likely
reflecting the disordered nature of the contained VWF.
Similar to heterozygous expression, homozygous rVWF33-34del
demonstrated a mild reduction in total VWF:Ag (;53% [P ,
.0001]; Figure 1A), but very little impact on secretion (ratio, 0.73;
Figure 1C). Microscopy revealed that rVWF33-34del produced
VWF ER Golgi Merge
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Figure 3. Widefield fluorescence microscopy of recombinant homozygous in-frame deletions. HEK293 cells were transfected with WT rVWF only (A-D) and either
rVWF3del (E-H), rVWF32-34del (I-L), or rVWF33-34del (M-P). Cells were fixed and stained for VWF (green), ER (red), and Golgi (magenta). Scale bars, 5 mm.
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pseudo-WPB that appeared very similar to WT (Figures 3M-P and
4G-H). Although a number of smaller and rounder pseudo-WPB
structures were present, similar structures were present in the WT.
Therefore, it is unclear if rVWF33-34del pseudo-WPB displayed
any significant morphological differences or aberrations compared
with WT. The level of ER-localized VWF was also comparable to
that observed in WT.
Stimulated release of VWF
The ability of the mutants to release VWF after external stimulation
of transfected HEK293 cells with PMA was investigated. There was
a clear reduction in the ability to secrete VWF after stimulation in
cells transfected solely with mutant VWF (Figure 5); however, this
was diminished when cells were cotransfected with both WT and
mutant VWF to mimic the heterozygote state (Figure 5).
Ex3del disrupts VWF SP cleavage
The loss of 55 amino acids in ex3del includes 4 residues from the C
terminus of the VWF SP, which encompasses the SP cleavage site.
This region exhibits significant interspecies conservation around the
cleavage site (Figure 6A); suggesting that changes to this specific
amino acid motif may disrupt signal peptidase (SPase)–dependent
cleavage. In order to determine what impact this may have on SP
cleavage, further in silico analysis was performed. The first 40
residues of WT and ex3del VWF were analyzed. In WT sequence,
predicted cleavage after p.Cys22 agreed with the published VWF
SP cleavage site.29 This was indicated by a steep drop in the SP
score slope (S-score) after p.Cys22, a high cleavage score
(C-score), and a peak in the combined cleavage score (Y-score)
at p.Ala23 (Figure 6B). Analysis of ex3del also showed a similarly
high S-score, indicative of a true SP, which dropped off sharply but
was staggered across residues p.Gly19_Phe21 (Figure 6C). How-
ever, the C-score and Y-score were both low, with no clear indica-
tion of a functional cleavage site (Figure 6C).
Discussion
This study aimed to investigate the contribution of CNV to disease
phenotype within the MCMDM-1VWD cohort. MLPA analysis iden-
tified heterozygous deletions in 6 IC, which tracked with disease





























Figure 4. SIM imaging of pseudo-WPB formation in recombinant homozy-
gous in-frame deletions. Expression of WT rVWF produced numerous pseudo-
WPB (A), which, on close inspection, had bright outer membrane staining (B).
(C) rVWF3del expression produced a diffuse, speckled network-like staining pattern.
(D) No large VWF-positive structures were visible. (E) rVWF32-34del expression
also produced a more diffuse staining pattern, although with apparent VWF-positive
structures. (F) However, the VWF-positive structures displayed uniform staining in-
tensity and nonuniform structure, possibly representing aggregates of VWF oligom-
ers. rVWF33-34del expression was able to form pseudo-WPB like structures (G);
however, numerous rounded structures were also visible (H). Scale bars, 5 mm
(A,C,E,G) and 1 mm (B,D,F,H). Panels B, D, F, and H are higher magnifications of










































































Figure 5. Stimulated secretion of in vitro-expressed rVWF. Data shows VWF:
Ag measured in supernatant divided by total VWF (lysate plus supernatant) following
1 hour of stimulation with PMA or vehicle (DMSO). Data were analyzed using
Student t test; DMSO versus PMA (***P , .001; ****P , .0001). Mean values for
n 5 3 triplicate measurements are shown (bars indicate standard deviation).
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cause of VWD in ;4% of the MCMDM-1VWD IC, similar to the
;6% contribution previously reported in French VWD1 IC,13 but
lower than the ;12% contribution recently reported in Czech
VWD1 IC.14 In the remaining 98 IC in which no CNV was identified,
deep intronic variation or alternative disease mechanisms (eg,
disruption of microRNA motifs or protein folding) may contribute to
clinical phenotype.2
Four of the IC with CNV had no previously identified causal variant.19
Three of the 4 IC were shown to have the previously identified and
characterized ex4-5del known to cause both VWD1 and VWD315;
the remaining IC had ex32-34del. In addition to being previously
reported in French VWD1 IC,13 a de novo ex32-34del has been
reported and characterized in an Italian IC with unspecified VWD.18
Unlike ex4-5del IC, which had the same deletion breakpoints as
previously reported, the ex32-34del IC had a unique breakpoint to the
Italian IC; c.54551279_58421998delins(7) (;5.2 kb) and c.5456-
66_584211316del (;3.4 kb),18 respectively. This is not surprising
because this study indicates that ex32-34del likely results from
nonhomologous end joining (NHEJ; as opposed to Alu-mediated
homologous recombination [AMHR] for ex4-5del15), suggesting that
ex32-34del breakpoints are likely to occur randomly.30 However,
the phenotype of both characterized ex32-34del IC is very similar,
including the slight increase in VWF clearance and abnormal
multimer profile.18
The remaining 2 IC both had previously reported variants. In 1,
a novel ex3del occurred in cis with p.Pro2722Ala, but given that
p.Pro2722Ala had no effect on in vitro VWF expression, it is likely
that ex3del is the actual cause of VWD1 in this IC. Like ex4-5del,
ex3del results from AMHR, suggesting that deletion breakpoints
would be conserved in other VWD patients with the same deletion.
The remaining IC had an ex33-34del occurring in trans with
p.Arg854Gln. The ex33-34del has been previously reported in both
VWD1 and VWD2,6,7,13 but has not been characterized. In this
study, NHEJ was the likely mechanism for this deletion, suggesting
that ex33-34del breakpoints are also likely to be random,30
similar to ex32-34del. However, as observed with ex32-34del,
clinical phenotype is likely consistent for all carriers of this deletion,
with the IC reported in this study reclassified as VWD2A on the
basis of their abnormal multimer profile.25 Although the clinical
phenotype in this IC is explained primarily by ex33-34del, coinher-
itance of p.Arg854Gln probably accounts for the observed reduction
in VWF:FVIIIB. As such, both ex3del and ex33-34del IC highlight
the importance of CNV screening, where previously identified
genetic variation does not fully explain clinical phenotype.
Heterozygous in vitro expression of the identified deletions all
demonstrated significant reductions in total VWF:Ag ranging from
;40% to ;60%, suggesting a reduction in VWF biosynthesis.
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Figure 6. In silico analysis of VWF SP cleavage. (A) Multiple sequence alignment showing the first 40 amino acids of VWF including the 22 residue SP (green bar).
Conserved residues are in shaded boxes. The red dashed line marks the SPase cleavage site and the red residues in the human alignment mark the start of ex3del. Note the
conservation of the ValLeuLeuAlaLeuAlaLeu hydrophobic motif, Cys prior to the cleavage site, Thr 3 residues prior to the cleavage site, and small residues such as Ala, Thr,
and Gly after the cleavage site. (B) SP and cleavage site prediction output for WT VWF. (C) SP and cleavage site prediction output for ex3del VWF. The shaded red box
indicates residues in exon 4.
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variants p.Arg1205His and p.Tyr1584Cys in HEK293T cells also
demonstrated reduced VWF biosynthesis,31 as has rVWF expres-
sion of p.Leu1696Arg and p.Pro1824His (although only in COS-7
cells, which do not form pseudo-WPB).32 An effect on VWF bio-
synthesis could occur at the level of transcription or translation.
Historically, a reported reduction in VWFmRNA levels in endothelial
cells (EC) from VWD1 patients,33 and more recently in EC from
VWD1 patients with known variants (including ex4-5del and
p.Tyr1584Cys),16 would suggest that it occurs at the level of
transcription.
Despite the reduction in total VWF:Ag, there was no significant
difference in VWF lysate levels, similar to observations made from
rVWF expression of p.Arg1205His and p.Tyr1584Cys.31 A more
accurate assessment of intracellular retention and reduced secre-
tion is to calculate the secretion ratio (VWF in supernatant/VWF in
lysate) for each mutant and WT. In this study, both heterozygous
expression of rVWF3del and rVWF32-34del demonstrated signif-
icant reductions in secretion (titration experiments confirming that
both have a dominant-negative affect on VWF), whereas heterozy-
gous rVWF33-34del expression resulted in only a mild secretion
defect. In support of this observation, widefield microscopy revealed
fewer pseudo-WPB/ER localization and increased Golgi/TGN
localization for rVWF3del and rVWF32-34del, respectively, com-
pared with normal pseudo-WPB formation/localization for rVWF33-
34del. This suggests that the efficient processing of rVWF3del and
rVWF32-34del is impaired; further supported by the reduced HMW
multimers observed for rVWF32-34del compared with WT rVWF.
Although this reduction in HMW multimers was more pronounced
in the IC-derived plasma sample, this is likely because of in vitro-
expressed VWF in HEK293 cells not fully undergoing the same
complex or regulated storage and secretion processes and flow
conditions that VWF experiences in vivo.34
In vitro expression therefore suggests that these deletions influence
VWF production via a combined influence on biosynthesis and
secretion. On the basis of the effective secretion (secretion ratio 3
percentage of WT), both rVWF3del and rVWF32-34del reduced
VWF levels by ;80%, which is not dissimilar to the reduction in
plasma VWF observed in the respective IC when compared against
plasma levels in unaffected family members (P9F11 [ex3del], ;75%
reduction; P9F3 [ex32-34del],;90% reduction). However, effective
secretion for rVWF33-34del, indicating a;50% reduction, is still not
as pronounced as that observed in the IC (;70%). Although effective
secretion in vitro more accurately reflects patient phenotype, it also
further highlights that other factors influencing VWF levels in vivo (eg,
flow) cannot be fully captured using a HEK293 cell model.
This study also performed microscopic characterization of homo-
zygous VWF storage and pseudo-WPB formation to gain further
insight regarding the impact of in-frame deletions. To date, few
studies have explored storage impairment caused by pathogenic
CNV; those that have, primarily focused on VWD2.12,16,17 In
addition to standard widefield microscopy, use of SIM enabled high-
resolution morphological analysis of pseudo-WPB. SIM uses spatially
structured or patterned illumination and computational reconstruction
to overcome the diffraction limitations of conventional light micros-
copy, resulting in a twofold resolution enhancement in both the lateral
and axial dimensions.35 Although this technology has been used
to image WPB in EC,36 it has not been used to characterize
WPB morphology in VWD. In this study, ex3del, ex32-34del, and
ex33-34del all displayed distinct microscopic phenotypes that
highlighted differences in their pathological mechanisms.
Both widefield and SIM imaging highlighted a lack of pseudo-WPB
formation following rVWF3del expression, with VWF staining
targeted to the ER. Previous studies have attributed ER retention
to disruption of key regions in the VWF D1 and D2 domains
essential for the trafficking of VWF dimers to the Golgi37 or for
forming a transient covalent bond with the D3 domain in the ER
prior to Golgi multimerization.38 Although these regions are
disrupted by ex4-5del, which also results in ER retention,16 they
are not disrupted by ex3del. Instead, in silico analysis indicated that
ex3del disrupts the C-terminus of the VWF SP, which targets
nascent VWF monomers to the ER membrane before its cleavage
by SPase. A SP consists of 3 core regions; the nonvariable region
adjacent to the SP cleavage site (21 to25 amino acids upstream)
contains specific small uncharged residues (eg, alanine or glycine)
at 21 and 23 that define the cleavage site.39 ex3del results in the
loss of 4 of 5 amino acids in this region, which suggests that,
although the VWF SP could still target the ER, SP cleavage would
be unlikely. In the heterozygous state, the ex3del allele is likely to
remain anchored to the ER (effectively acting as a null allele),
although it may also disrupt the processing and targeting of the WT
allele. The ex3del, therefore, may represent a novel pathogenic
mechanism in VWD1.
Despite similarities between rVWF3del and rVWF32-34del expres-
sion, microscopy indicated that ex32-34del formed VWF aggregates
in the ER. The ex32-34del extends into the VWF A3 domain;
characterization of VWF variants in the A domains (eg, p.Val1822Gly
within the A3 domain) suggests they impair VWF storage and
result in significant ER retention.40 In addition, reduced or lack of
desmopressin response associated with VWD1 variants in the A3
domain suggests that this region is essential for the biogenesis of
functional WPB.41 The A1 domain appears to play a role in
stabilizing VWF tubules42 and the A3 domain could potentially
perform a similar structural role. It is also possible that loss of the
A3 domain leads to severe misfolding and accumulation of mutant
VWF within the ER, leading to the VWF aggregations observed. In
some instances, the observation of large VWF-positive compart-
ments or vacuoles possibly reflects the dilated nature of the ER in
these mutants. ER dilation is a common observation in mutant
proteins retained in the ER, including a number of VWF mutants
that disrupt cysteine residues involved in the formation of intrachain
disulfide bonds.43
The fact that rVWF33-34del expression formed similar if not
identical pseudo-WPB to WT reflects the relatively mild affect this
deletion had on VWF multimers and secretion in vitro. This also
supports the suggestion that the A3 domain is important for WPB
formation, as this domain remains following ex33-34del. Therefore,
in vitro expression data for ex33-34del suggested that decreased
VWF biosynthesis is the most significant contributor to reduced
VWF levels. Although it is not clear how this variant causes
a reduction in VWF levels, despite forming WPB, this process may
be less efficient. Removal of exons 33-34 would likely result in
disruption to intrachain disulfide bonds and VWF misfolding,
potentially compromising packaging and tubulation within WPB.
The relative intensity of VWF antibody staining can potentially act as
a measure of VWF tubulation and packaging within WPB44;
disruption of VWF folding and the intraorganelle structure leads to
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a less compact state and provides an increased area of VWF
to which the antibodies can bind. Despite the morphological
similarities between pseudo-WPB formed by rVWF33-34del and
WT, numerous small round VWF-positive structures were also
found in rVWF33-34del. Interestingly, these rounded structures
appeared to have a more uniform fluorescence signal, perhaps
suggesting disordered VWF tubule formation and, therefore, a
reduction in density. The reduced HMW multimers observed for
rVWF33-34del and the corresponding IC supports this theory.
In summary, this study has provided further insight and un-
derstanding of the genetic mechanisms of VWD through identifi-
cation and characterization of in-frame VWF deletions. Furthermore,
in vitro expression and high-resolution microscopy indicates that in-
frame deletions lead to moderate and severe defects in VWF
biosynthesis and/or secretion that mimics the observed clinical
phenotype.
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